IP Library Granted Patent US 9,907,746
Granted Patent B2
US 9,907,746 · App. 13/377,371 · Granted Mar 6, 2018

Methods for preparing vesicles and formulations produced therefrom

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,907,746
App. No.
13/377,371
Granted
Mar 6, 2018
Kind
B2
Abstract

The present disclosure provides methods for preparing vesicles. In general, these methods include steps of providing a lyophilized lipid product and rehydrating the lyophilized lipid product with an aqueous solution comprising an antigen such that antigen-containing vesicles are formed. The lyophilized lipid product is prepared by dissolving vesicle-forming lipids in a polar-protic water-miscible organic solvent to produce a lipid solution and then lyophilizing the lipid solution. The present disclosure also provides antigen-containing vesicle formulations prepared using these methods. The present disclosure also provides kits that include a lyophilized lipid product in a first container and an aqueous solution comprising an antigen in a second container.

Claims (12)

1. A method of entrapping antigens within lipid vesicles, wherein the method comprises:

dissolving vesicle-forming lipids in tert-butanol to produce a lipid solution, wherein the lipid solution comprises 1-monopalmitoyl glycerol, dicetylphosphate, cholesterol, and a bile acid comprising sodium deoxycholate, at a ratio of 5:1:4:0.5;

lyophilizing the lipid solution to produce a lyophilized lipid product; and

rehydrating the lyophilized lipid product with an aqueous solution comprising an antigen consisting of an attenuated or inactivated virus such that antigen-containing lipid vesicles are formed.

2. The method of claim 1 , wherein the aqueous antigen solution further comprises a lyoprotectant.

3. The method of claim 2 , wherein the lyoprotectant is sucrose.

4. The method of claim 1 , wherein the attenuated virus or inactivated virus is hepatitis A or influenza.

5. The method of claim 1 , further comprising a step of adding an adjuvant after the antigen-containing lipid vesicles are formed.

6. The method of claim 1 , wherein the lyophilized lipid product comprises an adjuvant.

7. The method of claim 1 , further comprising a step of lyophilizing the antigen-containing lipid vesicles.

8. The method of claim 7 , further comprising a step of rehydrating the antigen-containing lipid vesicles after they have been lyophilized.

9. The method of claim 1 , wherein the antigen exhibits reduced antigenic integrity upon exposure to tert-butanol.

Assignments (6)
SECURITY INTEREST Recorded Jul 20, 2023
From: VARIATION BIOTECHNOLOGIES INC.
To: K2 HEALTHVENTURES LLC, AS CANADIAN COLLATERAL AGENT
Reel/Frame 064325/0840 →
RELEASE OF SECURITY INTEREST Recorded May 22, 2020
From: PERCEPTIVE CREDIT HOLDINGS, LP
To: VARIATION BIOTECHNOLOGIES (US), INC.
Reel/Frame 052744/0586 →
RELEASE OF SECURITY INTEREST Recorded May 22, 2020
From: PCOF 1, LLC
To: VARIATION BIOTECHNOLOGIES (US), INC.; VBI VACCINES (DELAWARE), INC.; VARIATION BIOTECHNOLOGIES INC.
Reel/Frame 052744/0622 →
SECURITY INTEREST Recorded Dec 20, 2016
From: VARIATION BIOTECHNOLOGIES (US), INC.
To: PERCEPTIVE CREDIT HOLDINGS, LP
Reel/Frame 041038/0668 →
SECURITY INTEREST Recorded Aug 8, 2014
From: VARIATION BIOTECHNOLOGIES (US), INC.; VBI VACCINES, INC.; VARIATION BIOTECHNOLOGIES INC.
To: PCOF 1, LLC
Reel/Frame 033501/0329 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2012
From: ANDERSON, DAVID E.; DIAZ-MITOMA, FRANCISCO; LE, HOANG-THANH
To: VARIATION BIOTECHNOLOGIES, INC.
Reel/Frame 027964/0934 →